| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $3.2M | +0.5% | +53.4% |
| SG&A Expense | $1.0M | -30.1% | -3.7% |
| Operating Income | -$4.3M | +10.2% | -32.5% |
| Net Income | -$4.2M | +12.3% | +18.0% |
| EPS (Basic) | $4.64 | -51.8% | +609.9% |
| EPS (Diluted) | $4.64 | -51.8% | +609.9% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $7.9M | -17.6% | +2174.3% |
| Current Assets | $8.1M | -19.6% | +1162.6% |
| Total Assets | $8.3M | -18.8% | +903.6% |
| Current Liabilities | $5.3M | +71.7% | +14.9% |
| Total Liabilities | $5.5M | +66.3% | +14.3% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$11.3M | — | — |
| Capital Expenditures | $76K | — | — |
| Investing Cash Flow | -$76K | — | — |
| Financing Cash Flow | $13.5M | — | — |
| Free Cash Flow | -$11.4M | — | — |
| $2.8M |
| -60.0% |
| +168.4% |